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Abstract 
A profile of impurities in bortezomib anhydride, produced by a recently 
developed convergent technology, has been characterized. HPLC-MS analysis 
of the drug essence revealed three impurities: an epimer of bortezomib, 
resulting from partial racemization of L-phenylalanine’s stereogenic center 
during the chemical synthesis, and two epimeric products of oxidative 
degradation of bortezomib, in which boron is replaced by the OH group. The 
impurities were obtained by chemical synthesis and characterized by physical 
methods. 
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Introduction 
Bortezomib (Velcade) 1 (Fig. 1) is the first-in-class proteasome inhibitor anti-cancer drug. It 
is approved in the US for the treatment of relapsed multiple myeloma and mantle cell 
lymphoma  [1]. Bortezomib acts as a highly selective reversible inhibitor of 26S 
proteasome, an ATP-dependent 2.4 MDa multicatalytic proteinaceous complex, regulating 
protein expression and function by degrading polypeptides and proteins, marked by 
ubiquitinilation. In neoplastic cells, proteosome inhibition may prevent degradation of pro-
apoptotic factors, leading to cell death [2–5]. 68  A. S. Ivanov, S. V. Shishkov, and A. Zhalnina:   
Sci Pharm. 2012; 80: 67–75 
N
N
O
N
O
N
H
H
N
N
O
N
O
N B
H
H
OH
OH
B
O
O R
B
O
R
B
R
= R
1 2  
Fig. 1.   
Bortezomib is available as a sterile lyophilized powder in single-dose vials, containing 
3.5 mg of the active pharmaceutical ingredient and 35 mg of mannitol. The essence of 
bortezomib is produced in the form of trimeric boronic anhydride 2. During the formulation, 
mannitol reacts with boroxine 2 to form the corresponding stable monomeric diester. The 
latter is hydrolyzed to release the active boronic acid 1 on reconstitution of the drug in 
saline solution for injection [6]. 
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Results and discussion 
Earlier it was shown that oxidative degradation of commercially available bortezomib-
mannitol adduct in a sterile 0.9% solution of NaCl in deuterated water led to formation of 
two products 4a and 5 as identified by NMR, ESI-MS, and MALDI spectrometry [7]. In 
another study, treatment of boronic acid 1 with hydrogen peroxide in 1.1 mM aqueous 
solution at 20 °C gave rise to alcohol 4a, retaining absolute configuration of the parent   Synthesis and Characterization of Organic Impurities in Bortezomib Anhydride Produced by …  69 
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molecule. However, when oxidation was carried out in PEG300 : EtOH : H2O (4:1:5), initial 
oxidation product 4a was undergoing a rapid isomerization to 4b and further degradation 
to amide 6. Also, acidic conditions (pH 1–2) accelerated isomerization of 4a; in contrast, 
alkaline conditions (pH 11–12) led to quantitative transformation of 4a into amide 6 [8] 
(Fig. 2). 
Recently, we reported a new efficient synthesis of bortezomib anhydride 2 employing a 
convergent approach  [9]. According to the ICH guidelines  (25 October 2006),  all the 
impurities that exceed the identification threshold of 0.1% are to be characterized [10]. To 
comply with these recommendations, we investigated the profile of impurities in the 
bortezomib anhydride essence, produced by the abovementioned method. HPLC-MS 
analysis of 99.6% pure essence 2 revealed three organic impurities: 3, 4a, and 4b in the 
ratio of 0.16, 0.13 and 0.07 % (Fig. 3). 
 
Fig. 3.   
Obviously, impurity 3 originates from partial racemization of L-phenylalanine’s chiral center 
during the chemical synthesis of bortezomib. It was shown that the use of TBTU in the 
fragment condensation between N-pyrazinecarbonyl-L-phenylalanine and an amino 
component resulted in a low degree of racemization as compared to N,N'-carbonyl-
diimidazole (CDI) [9]. However, even on activation with TBTU, the stereochemical integrity 
of the carboxy component is lost to some extent. This process is believed to proceed via 
an oxazolone intermediate (Scheme 1) and is favored by polar solvents and electron-
withdrawing N
α-acyl groups, such as pyrazinoyl [11]. 70  A. S. Ivanov, S. V. Shishkov, and A. Zhalnina:   
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Sch. 1. 
Impurities 4a,b are the products of degradation of boronic acid 1 or trimeric anhydride 2, 
which arise because of  oxidation of B–C bond with atmospheric oxygen. Oxidative 
deboronation is also the principal biotransformation pathway of bortezomib in humans [12]. 
To obtain compounds 3 and 4a,b in the essentially pure form and in an amount sufficient 
for characterization, study of properties and use as references in chromatographic 
analysis, we performed their synthesis. Thus, epi-bortezomib 3 was synthesized starting 
from  D-isomer of phenylalanine (Scheme 2).  D-Phe was silylated with N,O-bis(trimethyl-
silyl)acetamide (BSA) to give the corresponding N,O-bis-silyl derivative. The latter was 
reacted with pyrazinecarboxylic acid imidazolide, generated from pyrazinecarboxylic acid 
and CDI, to give N-pyrazinecarbonyl-D-phenylalanine  6  after aqueous work-up. 
(1S,2S,3R,5S)-pinanedioxy-N-pyrazinoyl-D-phenylalanyl-L-leucineboronate 8, was synthe-
sized according to a previously developed procedure [9]. Fragment condensation between 
carboxylic acid 6  and amine 7  was achieved using TBTU as a coupling agent. 
(1S,2S,3R,5S)-Pinanediol ester of epi-bortezomib 8 was isolated and transformed into epi-
bortezomib  3  by an exchange reaction with isobutylboronic acid under strongly acidic 
conditions in a biphasic mixture of aqueous methanol-hexane. The (1S,2S,3R,5S)-
pinanediol chiral auxiliary was recovered as the corresponding isobutylboronate. After 
crystallization from ethyl acetate compound 3  was obtained in the form of trimeric 
anhydride (similar to bortezomib anhydride 2).    Synthesis and Characterization of Organic Impurities in Bortezomib Anhydride Produced by …  71 
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Sch. 2.   
To obtain degradants 4a,b, we carried out oxidation of boroxine 2 with aqueous hydrogen 
peroxide in methanolic solution. After evaporation of the solvent, both products were 
obtained in the essentially pure form as a 39:61 mixture of diastereomeres. LC-MS 
analysis showed similar main peaks for each diastereomer with m/z 339.4, corresponding 
to dehydrated molecular peaks [M − H2O + H]
+.  Therefore,  the molecular weights were 
356. Even molecular masses indicated that the molecules’ backbones, containing even 
number of nitrogen atoms, were intact. On the other hand, the absence of boron atom in 
the molecules was seen from the absence of characteristic boron isotope pattern (20% 
10B 
and 80% 
11B). Separation of 4a and 4b, prepared from monomeric boronic acid 1 using 
isocratic reverse phase HPLC, was reported by Wu, et al.; 
1H and 
13C NMR spectra of the 72  A. S. Ivanov, S. V. Shishkov, and A. Zhalnina:   
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diastereomeric mixture were in accordance with those reported for the separate 
diastereomers [8].
 
Experimental 
Chemicals 
Bortezomib anhydride (2)  and (1S,2S,3R,5S)-pinanedioxy-(R)-1-ammonium-3-methyl-
butane-1-boronate trifluoracetate (7)  were synthesized according to the previously 
developed procedures [9]. All the reagents and solvents were obtained from commercial 
sources. Diethyl ether was distilled from sodium benzophenone ketyl. Argon was dried by 
passing through a drying column.  
Equipment 
Melting points were measured in open capillary tubes with OptiMelt MPA100 instrument. 
Optical rotations were determined on AA-55 Polarimeter at 20 °C. NMR spectra were 
recorded with an Avence II 600 and Bruker AMX-360 spectrometers. Chemical shifts were 
quoted in parts per million downfield from Si(CH3)4 (δ=0 ppm).  
HPLC and HPLC-MS analysis 
HPLC analysis was performed at room temperature (ca. 20 °C) on Agilent 1200 instrument 
with UV detection at 270 nm. Chromatographic separation was carried out in a C18 
250×4.6 mm column (Knauer, Kromasil 100-5 sorbent). Flow rate was kept at 1.0 mL/min. 
Mobile phases were A (acetonitrile-water-HCOOH 300:700:1 v/v/v) and B (acetonitrile-
water-HCOOH 800:200:1). Elution mode was 100% A during 5 min, gradient of B 
0100% during 15 min, and gradient of B 1000 during 2 min. LC-MS analysis was 
performed on Waters Quattro API instrument with 2695 separation module and a diode 
array detector, working in the range of 220–500 nm. The HPLC system was coupled with a 
quadrupole mass spectrometer with an electrospray ionization (ESI) source, operating in 
the positive mode. Chromatographic separation was carried out in a 100×1 mm C18 XTerra 
column (Waters Co., 3.5 µm) using a linear gradient elution of eluents A (0.1%, v/v TFA in 
water) and B (0.1%, v/v TFA in acetonitrile). Flow rate was set at 1.0 mL/min. 
Synthesis 
N
α-(Pyrazin-2-ylcarbonyl)-D-phenylalaninamide (6) 
A solution of silylated D-phenylalanine was prepared by addition of BSA (66 g, 325 mmol) 
during 1 h to a stirred suspension of D-phenylalanine (26.5 g, 161 mmol) in DCM (0.2 L) 
and stirring the mixture at room temperature for 17 h. The solution of N-pyrazine-
carbonylimidazole was prepared by slow addition of N,N’-carbonyldiimidazole (34.0 g, 
210 mmol) to a stirred suspension of pyrazinecarboxylic acid in DCM (0.4 L) at r.t. with 
subsequent reflux of the mixture for 17 h. To a reaction mixture, containing pyrazine-
carboxylic acid imidazolide, a solution of silylated D-phenylalanine was added during 2 h, 
and the resulting solution was stirred for 17 h at r.t. After that the dichloromethane solution 
was washed with aqueous citric acid (80 g of citric acid monohydrate per 0.5 L of D.M. 
water), aqueous phase was extracted with ether (0.3 L), and the DCM and ether solutions 
were combined, washed with water (2×0.2 L) and dried over anhydrous sodium sulfate. 
The solvents were concentrated under vacuum to the volume of 0.1 L and cooled in the   Synthesis and Characterization of Organic Impurities in Bortezomib Anhydride Produced by …  73 
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fridge. The amorphous precipitate formed was filtered off, washed with DCM and dried to 
obtain 27.2 g of yellow powder. Isol. yield 63 %. M.r. 169.5–170.9 °C. [Found: C, 61.85; H, 
4.90; N, 15.32. C14H13N3O3 requires C, 61.99; H, 4.83; N, 15.49.]; [α]D
20 −12.0 (c 1.0, 
MeOH). m/z (ESI-MS) 272 (M+H
+). 
1H NMR (360 MHz, acetone-d6, TMS): δ 9.22 (d, 1H, J 
= 1.4 Hz, CHpyr), 8.83 (d, 1H, J = 2.5 Hz, CHpyr), 8.63 (dd, 1H, J = 2.5, 1.44 Hz, CHpyr), 
8.39 (br d, 1H, NH), 7.40–7.10 (m, 5H, CHPh), 5.00 (m, 1H, αCHPhe), 3.34 (m, 2H, CH2Ph); 
13C NMR (90 MHz, DMSO-d6, TMS): δ 172.4, 162.6, 147.8, 144.1, 143.5, 143.4, 137.4, 
129.1 (2C), 128.2 (2C), 126.5, 53.5, 36.3. 
(1S,2S,3R,5S)-Pinane-2,3-dioxy N-pyrazinecarbonyl-D-phenylalanine-L-leucineboronate 
(N-{(1R)-3-Methyl-1-[(3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methano-1,3,2-
benzodioxaborol-2-yl]butyl}-Nα-(pyrazin-2-ylcarbonyl)-D-phenylalaninamide, 8) 
(1S,2S,3R,5S)-Pinane-2,3-diol-(R)-1-ammonium-3-methylbutane-1-boronate trifluoracetate 
(15.0 g, 40 mmol),  N-pyrazinecarbonyl-D-phenylalanine (10.7 g, 40 mmol), and TBTU 
(14.0 g, 44 mmol) were suspended in DCM (150 mL) under argon at −5 °C. A solution of 
DIPEA (20 mL, 123 mmol) in DCM (75 mL) was added dropwise over 2 h while stirring. 
The mixture was stirred at −5 °C for another 1 h and then at room temperature until the 
solution was clear. After that the solution was washed with water (75 mL), 10% aqueous 
K2CO3 (3×50 mL), 10% aqueous citric acid (75 mL), D.M. water (75 mL), and dried over 
anhydrous sodium sulfate. DCM was removed under vacuum, and the residue dissolved in 
ether (80 mL) and filtered through a pad of silica gel (180 mL of SiO2, eluent – ether). The 
solution obtained was evaporated under vacuum to yield 16.8 g of a glassy substance. 
Isol. yield 82%.  M.r. 60.8–82.6 °C. M/z  (ESI-MS): 367.28 (M−152+H
+), 519.39 (M+H
+), 
541.35 (M+Na
+). 
1H NMR (360 MHz, acetone-d6, TMS): δ 9.20 (d, 1H, J = 1.44 Hz, CHpyr), 
8.82 (d, 1H, J = 2.2 Hz, CHpyr), 8.63 (m, 1H, CHpyr), 8.40 (br d, 1H, NH), 7.61 (br s, 1H, 
NH), 7.10–7.33 (m, 5H, CHPh), 4.93 (m, 1H, αCHPhe), 4.30 (dd, 1H, J = 8.6, 1.8 Hz, 
CHpinane–O), 3.2 (t, 2H, CH2Ph), 3.05–0.7 (m, 25H, αCH–B, 5CH3, 3CH2, 3CH); 
13C NMR 
(75 MHz, CDCl3, TMS): δ 170.5, 162.5, 147.1, 144.0, 142.5, 136.3, 129.2 (2C), 128.2 (2C), 
126.6, 85.3, 77.5, 53.7, 51.3, 39.8 (CH2), 39.4, 38.5 (CH2), 38.3, 37.9, 35.7, 35.4 (CH2), 
28.4, 26.9, 26.1 (CH2), 25.9, 23.8, 22.7, 21.8. 
N-Pyrazinecarbonyl-D-phenylalanine-L-leucineboronic acid  
(N,N',N''-{Boroxin-2,4,6-triyltris[(1R)-3-methylbutane-1,1-diyl]}tri[Nα-(pyrazin-2-ylcarbonyl)-
L-phenylalaninamide], 3) 
(1S,2S,3R,5S)-Pinanedioxy-N-pyrazinecarbonyl-D-phenylalanyl-L-leucineboronate 
(15.84 g, 31 mmol) and isobutylboronic acid (4.7 g, 46 mmol) were dissolved in methyl 
alcohol (120 mL). To this solution hexane (120 mL) and 1N hydrochloric acid (65 mL) were 
added. The resulting biphasic mixture was stirred for 17 h at r.t. The lower aqueous layer 
was separated, washed with hexane (3x15 mL), basified with sodium bicarbonate (ca. 
6.7 g) to pH 5, and stirred for 30 min. The mixture was concentrated under vacuum and 
extracted with ethyl acetate (2×150 mL). The organic phase was washed with water 
(30 mL) and dried over anhydrous sodium sulfate. The solvent was removed under 
vacuum, and the residue crystallized from ethyl acetate (100 mL) at 60 °C. The precipitate 
was filtered off, washed with ethyl acetate and vacuum-dried to give 8.0 g of white powder. 
Isol. yield 68%. M.r. 186.2–195.7 °C (dec.). [α]D
20  −6.0 (c  1.0, DMF).  δH  (600  MHz, 
DMSO-d6) 0.76 (s, 1H, CH3), 0.77 (s, 1H, CH3), 1.16, 1.33 (2m, 2H, CH2(CH3)2), 1.57 (m, 
1H, CH(CH3)2), 2.63 (m, 1H, αCHB), 3.14 (m, 2H, CH2Ph), 4.94 (m, 1H, αCHPhe); 7.14–
7.25 (m, 5H, Ph), 8.71 (m, 1H, NH), 8.85(d, 1H, CHpyr, J 2.4 Hz), 8.86-8.88 (m, 2H, CHpyr, 74  A. S. Ivanov, S. V. Shishkov, and A. Zhalnina:   
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NH), 9.09 (d, 1H, CHpyr, J 1.2 Hz); δC (150 MHz, DMSO-d6) 20.69, 22.57, 22.82, 25.00, 
37.19, 40.07, 43.02, 51.69, 126.44, 128.05 (2C), 129.22 (2C), 136.87, 143.27, 143.46, 
144.06, 147.66, 162.53, 170.25, 172.78. 
Oxidation of bortezomib anhydride 2 
(N-[(1R)-1-hydroxy-3-methylbutyl]-Nα-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide, 4a, 
(N-[(1S)-1-hydroxy-3-methylbutyl]-Nα-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide, 4b) 
3% Aqueous hydrogen peroxide (10 mL) was added to a solution of bortezomib anhydride 
2 (5.0 g, 13 mmol) in methanol (20 mL), and the resulting solution was stirred at r.t. for 3 h. 
The solvent was evaporated under vacuum, and the residue dissolved in diethyl ether 
(100 mL), filtered through the pad of silica gel (50 mL) and eluted with diethyl ether. The 
ethereal solution was evaporated to dryness to yield 3.9 g of the product as a mixture of 
epimeric alcohols 4a,b in the ratio of 39:61. Isolated yield 83%. 
1H and 
13C spectra were in 
agreement with those reported for the separate diastereomers [8]. 
Conclusions 
We have studied the profile of impurities in bortezomib anhydride, synthesized by a 
previously developed convergent approach. Three organic impurities, including one which 
was previously unknown, were identified, synthesized and characterized. 
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